Mon 18 Nov 2019 AgilVax to Present Positive Preclinical Data for Monoclonal Antibody Targeting xCT at the American Association for Cancer Research’s Tumor Immunology and Immunotherapy Conference Read More
Wed 29 May 2019 AgilVax Triggers $2 Million Phase II Fast Track SBIR Grant and Initiates GMP Manufacturing Read More
Wed 09 Jan 2019 AgilVax Elects Dr. David T. Hung, Former Founder and CEO of Medivation, to Its Board of Directors Read More
Tue 07 Aug 2018 AgilVax Awarded $2.3 Million SBIR Fast Track Grant to Advance the Development of AX09 for Triple Negative Breast Cancer Read More
Tue 15 May 2018 AgilVax Closes A1 Financing to Expand Pre-IND Studies for AX09 In Triple Negative Breast Cancer Read More
Thu 04 Jan 2018 AgilVax to Attend J.P. Morgan Healthcare Conference, Biotech Showcase™ 2018 & RESI San Francisco 2018 Read More
Tue 05 Dec 2017 New Scientific Publication Supports AgilVax’s Novel Immunotherapy Development for Metastatic Breast Cancer Read More
